Moderna is offering good news from the company's phase 3 trials.
Preliminary results show Moderna's COVID-19 vaccine is more than 90% effective for at least six months after vaccination.
The vaccine was also found to be more than 95% effective against severe disease.
To date, the company has delivered about 132 million doses of its vaccine globally.
Moderna also announced its trials for kids 12-17 is fully enrolled with about 3,000 U.S. participants, and its trials for children 6 months through 11 years old is in the process of enrolling.